Related Experiment Video
Updated: Dec 30, 2025
09:00
A Sample Preparation Pipeline for Microcrystals at the VMXm Beamline
Published on: June 17, 2021
3.3K
Benchmarking a commercial proton therapy solution: The Paul Scherrer Institut experience
Sara Rosas1, Francesca M Belosi1, Nicola Bizzocchi
1Zentrum für Protonentherapie, Paul Scherrer Institut, Villigen, Switzerland.
The British Journal of Radiology
|January 17, 2020
Summary
This study benchmarks Eclipse™ against PSI-Plan for proton therapy, finding Eclipse™ offers superior target coverage and homogeneity. Both systems effectively spare organs at risk, though PSI-Plan requires more pencil beams.
Area of Science:
- Medical Physics
- Radiation Oncology
- Medical Technology
Background:
- Paul Scherrer Institut (PSI) has utilized its in-house treatment planning system (TPS), PSI-Plan, for over 20 years in proton beam scanning proton therapy.
- Over 1500 patients with deep-seated tumors have been treated using PSI-Plan and custom-built gantries.
Purpose of the Study:
- To benchmark the performance of a new TPS/Gantry system (Eclipse™) against a well-established system (PSI-Plan).
- To evaluate the suitability of commercial systems for emerging proton therapy centers.
Main Methods:
- 31 patient cases across 7 anatomical sites and 12 indications were re-planned using Eclipse™.
- Plans were compared to those optimized with PSI-Plan based on target coverage, plan quality, organ-at-risk (OAR) sparing, and pencil beam count.
Main Results:
- Eclipse™ demonstrated improved target coverage and homogeneity compared to PSI-Plan.
- PSI-Plan offered superior plan conformity.
- Both TPS met clinical constraints for OAR sparing.
- PSI-Plan required an average of 3.4 times more pencil beams per plan.
Conclusions:
- Both Eclipse™ and PSI-Plan can generate satisfactory proton therapy plans.
- Eclipse™ provides enhanced target coverage and homogeneity without compromising OAR sparing.
- This benchmark is valuable for new proton therapy centers adopting commercial systems.
